

Drug Utilization Review Board

Meeting Minutes

Thursday, October 12, 2023

7:15 a.m. to 8:30 a.m.

Google Meet

Board Members Present:

James Keddington, DDS
Judith Turner, DVM, PharmD
Jennifer Brinton, MD
Katherine Smith, PharmD

Neal Catalano, PharmD
Kumar Shah, MSc, PEng
Michelle Hofmann, MD
Sharon Weinstein, MD

Board Members Excused:

Colby Hancock, PharmD
Susan Siegfroid, MD

Eric Cannon, PharmD, FAMCP, Board
Chair

Dept. of Health/Div. of Health Care Financing Staff Present:

Yoon Kim-Butterfield, MD Medical
Director
Bryan Larson, PharmD
Ngan Huynh, PharmD
Luis Moreno, PharmD

University of Utah Drug Regimen Review Center Staff Presenter:

Monet Luloh, PharmD

Other Individuals Present:

Tony Patterson, State of Utah
Alexandra Jarvis, Sobi
Michael Zarob, Alkermes
Monet Luloh, University of Utah DRRC
Valerie Gonzales, University of Utah
DRRC
Miles Rooney, Optum
Anna Fondario, DHHS Public Health
Equity
Chad Duncan

Gary Parenteau, Dexcom
Matthew Call
Natalie Rose, Gilead
Northwest AMCP Affiliate
Jeff White, Sumitomo Pharma America
Bob
Amanda Haikalis, Duchesnay

Meeting conducted by: Ngan Huynh, PharmD

Drug Utilization Review Board

Meeting Minutes

1. **Welcome:** Ngan Huynh opened the meeting and reminded everyone who attended the meeting to identify themselves via meeting chat or by sending an email to medicaidpharmacy@utah.gov. Ngan Huynh announced a quorum.
2. **Review and Approval of Choose an item Minutes:** Kumar Shah motioned to approve the minutes from September. Katherine Smith seconded the motion. Unanimous approval.
3. **Housekeeping:**
 - a. **Public Meetings Act Training by Tony Patterson, Assistant Attorney General, State of Utah**
 1. Information
Please refer to the recording available via YouTube.
 2. Board Discussion
 - a. Kumar Shah asked if there are any punitive damages that can be claimed as a result of not faithfully following the compliance?
 - b. Tony Patterson answered: "No." He further explained that the Act primarily provides two different avenues of relief: 1) the Class B misdemeanor, or criminal charges against the body or individual members that violate the Open Public Meeting Act; and 2) the court will force the public body to go back and redo a discussion [or meeting] to give everyone an opportunity to provide their input when notice of the meeting agenda was not properly documented, etc. The second avenue is the one that has been acted upon by Utah courts.
4. **Review:**
 - a. **Sickle Cell Disease (SCD) presented by Monet Luloh, PharmD**
 1. Information
Please refer to the recording available via YouTube.
 2. Public Comment
None

Drug Utilization Review Board

Meeting Minutes

3. Board Discussion

- a. Michelle Hofmann asked if there was collaboration of this report with the Office of Health Equity in the Department that is responsible for implementation of that senate bill around the registry. Ngan Huynh responded that Anna Fondario from the Division of Public Health Equity was present in the meeting. Anna Fondario said she is working with Vaughn and Brittany to coordinate internally looking at the different surveillance systems. They have also been coordinating regularly with Medicaid.
- b. Kumar Shah asked if there is an estimate of sickle cell cases we might be missing in Utah, and at what rate we might expect cases to increase. Monet Luloh responded by saying that she was not aware of an exact estimate on the number of individuals affected with SCD in Utah, but that it is something that we can expect will increase overtime based on demographic changes within our state.
- c. Kumar Shah also asked about the rate of SCD in other nationalities living in Utah; and if other nationalities do not have a problem with SCD. Monet Luloh said SCD is more predominant in African American and Hispanic populations, but she was not sure about other nationalities.
- d. Sharon Weinstein commended everyone for the work done on this as it is a multi-disciplinary effort. She wondered if the development of the program would include consultation for pain management for support of front-line clinicians given the complexities and regulations around opioid therapy.
- e. Ngan Huynh said that this report will be given to the legislature, and she acknowledged Dr. Weinstein's point.
- f. Sharon Weinstein asked if the board needed a motion for this topic. Ngan Huynh confirmed that a motion was not necessary.

4. Board Action

None

b. Beyfortus (nirsevimab-alip) presented by Ngan Huynh, PharmD

Drug Utilization Review Board

Meeting Minutes

1. Information

Please refer to the recording available via YouTube.

2. Public Comment

- a. Alexandra Jarvais from Sobe Medical Affairs presented clinical information on Synagis (palivizumab).

3. Board Discussion

- a. Jennifer Brinton said she feels grateful for having Beyfortus available for babies to help prevent complications from RSV. She noted that this would be a cost saving approach and asked to clarify if Beyfortus is not the same as the vaccine used for adults. Ngan Huynh confirmed that is correct. She further explained that Beyfortus is a monoclonal antibody for pediatric patients, and that the name of the vaccine for adults is called Abrysvo.
- b. Katherine Smith asked if we are reviewing prior authorization criteria for Beyfortus, and if Beyfortus will replace Synagis, or if it will be available along with Synagis? Ngan Huynh said Medicaid will not require prior authorization for Beyfortus which has open coverage for eligible patients. Providers/pharmacies enrolled in the Vaccines for Children (VFC) program can bill the supply to the VFC program and Medicaid will reimburse for the administration fee. Beyfortus will be available together with Synagis, however, Synagis requires prior authorization.

4. Board Action

None

5. Meeting Chat Transcript:

00:01:58.674,00:02:01.674

Jeff White: Jeff White - Sumitomo Pharma America (SMPA)

jeff.white@us.sumitomo-pharma.com

00:02:32.373,00:02:35.373

Alex Jarvais: Alexandria Jarvais - Sobi, NA alexandria.jarvais@sobi.com

Drug Utilization Review Board

Meeting Minutes

6. **The next meeting scheduled for Thursday, November 09, 2023**
Antidepressants in Children.

 7. **Public Meeting Adjourned:** Kumar Shah motioned to adjourn the meeting. Sharon Weinstein seconded the motion. Unanimous approval.
-

Audio recordings of DUR meetings are available online at:

<https://medicaid.utah.gov/pharmacy/drug-utilization-review-board?p=DUR%20Board%20Audio%20Recordings/>